ReviewPharmaceuticals (Basel, Switzerland)2021
2020 FDA TIDES (Peptides and Oligonucleotides) Harvest.
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- pH-Dependent Surface Charge Modulation of Peptide-Coated Poly(lactic-co-glycolic Acid) (PLGA) Nanoparticle for Drug Delivery in Ovarian Cancer.Molecules (Basel, Switzerland) · 2026Article
- Mice lacking β-arrestin-2 in melanocortin 4 receptor-expressing neurons show marked metabolic deficits.JCI insight · 2026Article
- Re-Evaluation of Fixed Dosing Versus Body Size-Based Dosing Approaches for Large Molecule Therapeutics in Adults.Clinical pharmacology and therapeutics · 2025Review
- Chitosan-Nanomaterials (Basel, Switzerland) · 2025Article
- Peptide-Drug Conjugates: A New Hope for Cancer.Journal of peptide science : an official publication of the European Peptide Society · 2025Review
- Regulatory Guidelines for the Analysis of Therapeutic Peptides and Proteins.Journal of peptide science : an official publication of the European Peptide Society · 2025Review
- Full sequencing of 100mer sgRNA via tandem mass spectrometry by targeted RNase H digestion with customized probes.Analytical and bioanalytical chemistry · 2025Article
- Advances of deep Neural Networks (DNNs) in the development of peptide drugs.Future medicinal chemistry · 2025Review
- An Improved P(V) Thio-Oligonucleotide Synthesis Platform.Organic letters · 2025Article
- Setmelanotide-mediated MC4R activation improves hypothalamic obesity via CaMKK2/AMPK pathways.Frontiers in pharmacology · 2025Article
- Porous silicon and silica carriers for delivery of peptide therapeutics.Drug delivery and translational research · 2024Review
- Peptide-Based Therapeutics in Cancer Therapy.Molecular biotechnology · 2024Review
- Article
- Review
- Biocompatible strategies for peptide macrocyclisation.Chemical science · 2024Review
- 2023 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Microtubule stabilising peptides: new paradigm towards management of neuronal disorders.RSC medicinal chemistry · 2023Review
- Quantification of Oligonucleotides Using Tandem Mass Spectrometry with Isobaric Internal Standards.International journal of molecular sciences · 2023Article
- Synthesis and Evaluation of a Monomethyl Auristatin E─Integrin αJournal of medicinal chemistry · 2023Article
- Recent advances in the development of therapeutic peptides.Trends in pharmacological sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling the global health crisis. The US Food and Drug Administration (FDA) has approved 53 new drug entities, six of which fall in the peptides and oligonucleotides (TIDES) category. The number of authorizations for these kinds of drugs has been similar to that of previous years, thereby reflecting the consolidation of the TIDES market. Here, the TIDES approved in 2020 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.